Finafloxacin

Base Information

• Chemical Name: Finafloxacin
• CAS No.: 209342-40-5
• Molecular Formula: C20H19FN4O4
• Molecular Weight: 434.849
• UNII: D26OSN9Q4R
• ChEMBL ID: CHEMBL1908370
• DSSTox Substance ID: DTXSID10175096
• Metabolomics Workbench ID: 152107
• NCI Thesaurus Code: C80638
• Nikkaji Number: J2.714.451I
• Wikidata: Q21011229
• Wikipedia: Finafloxacin
• Mol file: 209342-40-5.mol

Synonyms:3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2H)-yl)-1,4-dihydro-4-oxo-;finafloxacin;Xtoro

Chemical Property of Finafloxacin

Chemical Property:

• Boiling Point: 686.2±55.0 °C(Predicted)
• PKA: 6.38±0.50(Predicted)
• PSA: 107.59000
• Density: 1.57±0.1 g/cm3(Predicted)
• LogP: 1.61618
• Storage Temp.: -20°C
• XLogP3: -0.7
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 9
• Rotatable Bond Count: 3
• Exact Mass: 398.13903326
• Heavy Atom Count: 29
• Complexity: 806

Purity/Quality:

97% ^*data from raw suppliers

Finafloxacin ≥95% (HPLC) ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4CC5C(C4)OCCN5)F)C(=O)O
• Isomeric SMILES: C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O
• Recent ClinicalTrials: Proof-of-Concept Study of a Single Application of an Investigational Otic Suspension in Treatment of Acute Otitis Media With Tympanostomy Tubes
• Recent EU Clinical Trials: A Multi-Dose, Double-Blind, Double-Dummy, Active Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation
• Description: Finafloxacin, an antimicrobial agent of the 8-cyano subclass of fluoroquinolones, was approved by the US FDA in December 2014 for treatment of acute otitis externa, commonly known as swimmer’s ear, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin was developed by MerLion Pharmaceuticals in partnership with Bayer Health Care Pharmaceuticals, and the drug was licensed by Mer- Lion to Alcon (a division of Novartis) for development and commercialization for ear infections in North America. In contrast to other marketed fluoroquinolones, which display reduced activity in slightly acidic environments, finafloxacin exhibits increased antibacterial activity at pH 5–6, with minimum inhibitory concentration values that are 4- to 8-fold lower than at neutral pH. It is highly selective for bacterial type II topoisomerases, which are involved in bacterial DNA replication, transcription, repair, and recombination, and has broad spectrum antibacterial activity against Gram-positive and Gram-negative strains, including ciprofloxacin-resistant strains.
• Uses: Used for the preparation of naphthyridonecarboxylic acid derivatives as drugs for therapy of Helicobacter pylori infections and associated gastroduodenal illnesses.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Please select Metric Ton KG G Pound L ML

Email:

Company name:

Valid Period:

Detailed Requirements:

• Sample
• MOQ
• GMP
• FDA
• Price
  FOB CIF CFR EXW
• Urgent purchase

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

Remove

Submit

1

What can I do for you?
Get Best Price

Get Best Price for 209342-40-5 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-

Send

Send

Metric Ton KG G Pound L ML

Send

Send